Top Tips for Creating Patient Education Material
Information is an important part of the patient journey and central to the overall quality of each patient’s experience with your drug, treatment or product. To help you get…
Is Regionalisation of Phase IV Trials a Good Thing?
Regionalisation of phase IV trials because of payer differences sounds like a good thing in the short term. Improved market access, for one. But has anyone considered the longer term effects?
Competitive Intelligence and Competitor Strategy
Interesting article in PharmaVoice in April 2012 – regarding Competitive Intelligence and Competitor Strategy. The article rightly points out that Pharma is leaving good intel on the table –by not…
Evidence matters… of course it does!
Ruairi O’Donnell writes in the March 2012 issue of Pharmaceutical Market Europe that evidence matters. Of course it does. And particularly in market access activities, which is the context he…
Anatomy of a medical communications project manager
We thought we should provide some insight to the anatomy of our medical communications project manager
ISPOR Abstract Submission Open
The ISPOR 15th Annual European Congress Abstract Submission has opened today.
Taking place at the ICC Berlin, Germany ISPOR will be accepting abstract submissions which must be submitted through ISPOR’s online abstract system by June 26th 2012.
The Absence of Clinical Trial Data: Attack on Pharma
One of our Twitter followers @HealthEcoDigest recently blogged a podcast with the BMJ editor-in-chief Fiona Godlee and neuroscientist Professor Colin Blakemore. In the podcast, they are discussing whether a false…
Editorial: Putting the squeeze on pharma pricing in the EU
The world is a daily classroom on basic economics principles: from the Greece bailout, to the austerity measures in several EU countries, to debate over the Chinese yuan currency, to the American recession and Occupy Wall Street protests.
Pricing policy in Europe: of cars, football, and prescription drugs
There is a tug-of-war going on between the European Commission, with laws intended to protect the free market, and business sectors hoping to claim (or retain) exclusivity. National EU governments are using those laws to their advantage to obtain prescription drugs for the lowest prices.